DFTX
Definium Therapeutics, Inc.
36.20$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -12.0% | +121.2% | -2.7% | +19.3% | -5.5% | -8.9% | -3.7% | -10.6% | +85.8% | -8.8% | +177.3% | |
| – | -13.5% | +145.9% | -3.0% | +20.9% | -5.9% | -21.3% | -14.7% | +14.1% | +94.3% | -9.2% | +187.0% | |
| – | -15.3% | +153.1% | -3.6% | +21.5% | -7.3% | -69.7% | -59.7% | -40.2% | +1,191.8% | +1.8% | +149.6% | |
| – | -15.3% | +153.1% | -3.6% | +21.5% | -7.3% | -22.4% | -13.9% | +14.3% | +96.9% | -9.3% | +190.3% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -60.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +1.8% | +71.3% | -16.8% | -12.9% | +5.4% | -13.5% | +51.7% | +33.4% | +1.4% | +13.6% | +58.6% | |
| – | +3.5% | +102.4% | -35.9% | -20.5% | +16.8% | -21.5% | +24.5% | +72.3% | +2.0% | +21.6% | +93.8% | |
| – | -46.2% | +83.6% | -61.3% | -26.8% | -6.5% | +12.8% | +85.9% | +92.4% | -34.1% | +33.3% | -2.3% | |
| – | – | – | – | – | -10.1% | +0.8% | +86.9% | -2.0% | +0.5% | +0.5% | -10.6% | |
| – | -18.6% | +150.9% | +3.1% | +29.8% | -7.9% | -7.7% | -16.8% | -29.6% | +154.5% | -16.1% | +229.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.4% | +18.8% | +50.3% | +11.6% | +4.6% | +3.8% | -2.0% | +0.6% | +4.0% | +21.8% | +1.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.